• ACPA-positive RA arises from the interaction between primed immune systems and the articular connective tissue substrate. • ACPA-positive RA develops as thresholds of articular stiffness are crossed producing normal age incidence distributions. • Increases in articular stiffness at menopause account for the earlier age incidence peak in women. • Greater articular stiffness causes more severe RA in late-life may explain “difficult-to-treat” RA. • Arterial and articular stiffness correlate. This partly accounts for the excess cardiovascular disease in ACPA-positive RA. The dramatic scientific and therapeutic advances of the last century have transformed outcomes in the management of anti-CCP positive rheumatoid arthritis (ACPA + RA). However, therapeutic challenges remain. While ACPA + RA is fundamentally an immunological disease the Immuno-Biomechanical Model (IBM) adopts a novel perspective proposing that ACPA + RA is the outcome of the interaction between primed immune systems and the connective tissue substrate. The model starts with the simple premise that ACPA + RA develops as immunologically primed individuals cross biomechanical thresholds of articular stiffness and that subsequent RA severity is similarly influenced by articular stiffness. This biologically plausible model is based upon established RA epidemiology and observational studies informed by studies of connective tissue biomechanics. The hypothetical implications of the model are explored graphically revealing how changes in articular stiffness could explain the unimodal age incidence distributions, the earlier age peak in women, the paradox of increasing RA severity in the face of declining RA incidence in late-life and suggesting new potential mechanisms for delayed treatment failure and refractory RA. The model suggests that a component of the excess cardiovascular disease in ACPA + RA may have a biomechanical basis not influenced by standard immunotherapies that contributes to the persistence of excess CVD regardless of the therapeutic advances in RA therapeutics. The IBM presents a plausible hypothesis describing a landscape for further research with broad implications for the treatment of ACPA + RA.

• Mitochondrial silencing is defined as preserved structure with reduced apoptotic execution capacity • Hypoxia-induced mitochondrial silencing may permit survival in initiation–promotion. • Pathological angiogenesis may stabilize hypoxic niches that maintain silencing. • Silent mitochondria are proposed as a third apoptosis axis beyond pro/anti signaling. Cancer initiation and progression have traditionally been interpreted primarily through the accumulation of genetic mutations and the dysregulation of intracellular signaling pathways. At the same time, increasing evidence indicates that the tumor microenvironment—particularly hypoxia and pathological angiogenesis—plays a critical role in tumor cell survival, clonal selection, and therapeutic resistance. However, how genetic alterations and hypoxia-driven metabolic adaptation are functionally integrated during stepwise tumor progression remains incompletely understood. In this manuscript, we propose a dual hypothesis framework in which hypoxia-induced mitochondrial silencing and hypoxic niches maintained by pathological angiogenesis cooperatively shape cancer progression in hypoxia-prone solid tumors. Mitochondrial silencing is defined here as a functional mitochondrial state in which oxidative metabolism is suppressed and the executional capacity of mitochondria-dependent apoptosis is attenuated, despite the structural persistence of mitochondria. We further propose that this state functions as a third regulatory layer of apoptosis control, distinct from classical pro- and anti-apoptotic signaling pathways. As a second component of the hypothesis, we suggest that structurally and functionally abnormal tumor neovasculature generates spatially heterogeneous microenvironments characterized by limited red blood cell–mediated oxygen delivery but relatively preserved diffusion of glucose. Such hypoxic, glucose-accessible niches are predicted to preferentially select for and maintain cell populations adapted to mitochondrial silencing and glycolysis-dominant metabolism, thereby supporting clonal persistence, heterogeneity, and progression. Although this work does not present experimental data, it provides a testable conceptual framework that repositions mitochondrial functional state as a central integrator of genetic alterations and microenvironmental constraints, and offers new perspectives on apoptosis resistance and metabolic adaptation in hypoxic solid tumors.